Interestingly, ANXA1 was downregulated in primary breast tumors, but upregulated in normal breast tissues and in metastatic tumors, and breast cancer patients with high levels of ANXA1 have a poorer clinical prognosis 44-47, which is consistent with the expression changes of NTF4 in distinct breast tissues. This evidence concerns the gene NTF4 and metastatic neoplasm.